Acumen Pharmaceuticals, Inc. (ABOS) vs Freenome, Inc. (FRNM)

A side-by-side comparison of Acumen Pharmaceuticals, Inc. and Freenome, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

ABOS

Acumen Pharmaceuticals, Inc.

$154M

$2.13HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT

FRNM

Freenome, Inc.

$137M

$16.83HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT

Total return — ABOS vs FRNM

growth of $100 · dividends reinvested · last 1y

ABOS -5.8% (-5.8%/yr)FRNM +52.9% (+52.9%/yr)FRNM compounded faster over this window

ABOS FRNM

Metrics side by side

Total return (annualized)

Metric	ABOS	FRNM
Total return (1Y)	23.00%	N/A
Total return CAGR (3Y)	-21.95%	N/A
Total return CAGR (5Y)	-32.60%	N/A

FRNM is an index fund, so valuation, profitability, and per-company growth metrics don't apply — the head-to-head here is total return (price plus reinvested dividends).

Go deeper

Full ABOS analysis Full FRNM analysis Interactive comparison tool

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.